The strong survival and safety data is a significant catalyst for DRTSW. Expect short-term volatility as the market digests the ASCO presentation. Monitor upcoming IMPACT and ACAPELLA trial updates for further de-risking. The company may need to raise capital for larger trials, so watch for potential dilution.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $1.02entry
- T+1 · 6mo ago 0.00%α −0.14% · $1.02
- T+5 · 5mo ago 0.00%α +2.75% · $1.02
- T+20 · 5mo ago +189.22%α +190.51% · $2.95
- T+60 · 3mo ago +281.37%α +280.14% · $3.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026. Median OS for second-line metastatic patients was 11.2 months vs historical ~4-6 months, with a favorable safety profile (no treatment-related deaths). The data de-risks the platform and supports advancement of the IMPACT trial.
Key Facts
- Pooled analysis of three Phase I/II studies in locally advanced or metastatic PDAC.
- Second-line metastatic mOS: 11.2 months from enrollment (historical ~4-6 months).
- Second-line locally advanced mOS: 11.1 months from enrollment (historical ~9 months).
- Third-line metastatic mOS: 7.9 months from enrollment (historical ~4-7 months).
- Treatment-associated AEs in 36% of subjects, Grade ≥3 in 9%, no treatment-related deaths.
- Data presented at 2026 ASCO Annual Meeting.
Financial Impact
Positive clinical data for a pre-revenue biotech; no financial figures disclosed.
Risk Factors
- Early-stage, non-randomized data with small sample size.
- Need for larger randomized trials to confirm efficacy.
- Company is pre-revenue and may require additional financing.
- Regulatory approval path uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063182 |
| Document: ea0292770-6k_alpha.htm | 0001213900-26-063182 |
| Document: 0001213900-26-063182-index-headers.html | 0001213900-26-063182 |
| Document: 0001213900-26-063182-index.html | 0001213900-26-063182 |
| Document: 0001213900-26-063182.txt | 0001213900-26-063182 |
Track record
14 reports on DRTSW
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Viewing Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers